U.S. markets open in 5 hours 19 minutes
  • S&P Futures

    4,534.50
    +26.00 (+0.58%)
     
  • Dow Futures

    34,213.00
    +211.00 (+0.62%)
     
  • Nasdaq Futures

    15,944.25
    +74.50 (+0.47%)
     
  • Russell 2000 Futures

    2,170.00
    +23.70 (+1.10%)
     
  • Crude Oil

    66.38
    +0.81 (+1.24%)
     
  • Gold

    1,771.40
    -12.90 (-0.72%)
     
  • Silver

    22.34
    +0.00 (+0.00%)
     
  • EUR/USD

    1.1325
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    28.65
    +1.46 (+5.37%)
     
  • GBP/USD

    1.3310
    +0.0032 (+0.24%)
     
  • USD/JPY

    113.2260
    +0.4460 (+0.40%)
     
  • BTC-USD

    57,002.98
    +104.87 (+0.18%)
     
  • CMC Crypto 200

    1,452.33
    -16.75 (-1.14%)
     
  • FTSE 100

    7,121.39
    -47.29 (-0.66%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

Guardant Health to Report Third Quarter Financial Results on November 4, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., October 08, 2021--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after market close on Thursday, November 4, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211008005070/en/

Contacts

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Breen Weir
press@guardanthealth.com

Julie Johnson
julie.johnson@uncappedcommunications.com